Nautilus Biotechnology, Inc.
NAUT- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001808805
No open-market purchases or sales by Nautilus Biotechnology, Inc. insiders were filed in the last 90 days; 93 institutions reported holding it in 13F filings for Q2 2026, worth $93.7M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Nautilus Biotechnology, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 56 | 72 | +16 |
| Shares | 39.0M | 41.0M | +1.94M (+5.0%) |
| Value | $379.7M | $245.1M | −$134.7M (−35.5%) |
New holders (24)
Institutions that held Nautilus Biotechnology, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
Sold out (8)
Institutions that held Nautilus Biotechnology, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| 683 Capital Management, LLC | 267,454 | $2.70M |
| Point72 Asset Management, L.P. | 64,866 | $655.0K |
| Governors Lane LP | 55,560 | $561.0K |
| Prelude Capital Management, LLC | 49,500 | $500.0K |
| HRT Financial LP | 42,859 | $432.0K |
| Cowen and Company, LLC | 30,000 | $303.0K |
| Magnetar Financial LLC | 10,726 | $108.0K |
| FNY Investment Advisers, LLC | 5,000 | $50.0K |